Egypt Lung Cancer Therapeutics Market Report 2022 to 2030

Egypt Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Egypt Lung Cancer Therapeutics Market will reach a value of $174 Mn from $83 Mn in 2022, growing at a CAGR of 9.6% during 2022-2030. The Lung Cancer Therapeutics Market in Egypt is dominated by a few domestic pharmaceutical companies such as EIPICO, Pharco Pharmaceuticals, and El-Nasr Pharmaceutical Chemicals. The Lung Cancer Therapeutics Market in Egypt is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Egypt lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10EGPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Dr. Vishwa Modhia

Buy Now

Egypt Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Egypt Lung Cancer Therapeutics market will reach a value of $174 Mn from $83 Mn in 2022, growing at a CAGR of 9.6% during 2022-2030.

Egypt is a lower middle-income, developing country in North Africa that borders the Red Sea and the Mediterranean Sea. Lung cancer is the most dangerous cancer in Egypt, but it is only the fourth most prevalent cancer in men and is uncommon in women. This gender disparity in incidence is attributed primarily to disparities in tobacco smoking rates. Egypt continues to have one of the lowest rates of female smokers in the world. In Egypt, the survival rate for lung cancer is low when compared to other types of cancer. Only about 11% of persons with lung cancer will live for five years or longer.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Egypt reached 5,677 or 1.06% of total deaths. The age-adjusted Death Rate is 8.02 per 100,000 of population ranks Egypt 115^th in the world. Egypt's government spends 4.4% of its GDP on healthcare.

Egypt Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Egypt has 68 radiation therapy centres and 96 linear accelerators, respectively. Egypt has the biggest total number of oncologists and cancer centres in the Middle East and Africa, but one of the lowest health expenditures per capita when compared to other lower-middle-income countries. These aspects could boost Egypt's Lung Cancer Therapeutics market.

Market Restraints

The heterogeneity of diagnostic and therapeutic options remains the essence of Egypt's lung cancer dilemma. Egypt's specialised healthcare providers and facilities are insufficient to offer basic care to its 95 Mn-strong population. Furthermore, some university hospitals and cancer institutes had previously provided the fundamental standards for lung cancer therapy. Egypt lacks a nationwide screening programme, and the vast majority of patients come with either locally advanced or metastatic disease.

Targeted treatment and immunotherapy are substantially more limited in their availability. In the Levant and Egypt, for example, target therapy is only available in insurance-covered private sectors, whereas immunotherapy is more difficult to obtain. With a growing population, limited resources, and a lack of infection control techniques, Egypt still confronts serious disease management concerns today. These factors may deter new entrants into the Egypt Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Pharco Pharmaceuticals: Pharco Pharmaceuticals is an Egyptian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
EIPICO: EIPICO is an Egyptian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Amoun Pharmaceutical Company: Amoun Pharmaceutical Company is an Egyptian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Memphis Pharmaceuticals: Memphis Pharmaceuticals is an Egyptian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Ibn Sina Pharma: Ibn Sina Pharma is an Egyptian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
El-Nasr Pharmaceutical Chemicals: El-Nasr Pharmaceutical Chemicals is an Egyptian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer

Recent Notable Updates

June 2022: As part of the presidential initiative "100 Million Health," Egypt's Minister of Higher Education and Scientific Research and Acting Minister of Health and Population, Khaled Abdel Ghaffar, has announced the commencement of a sub-initiative for early identification of lung and colon cancers. This occurred during Abdel Ghaffar's evaluation of the African Center for Women's Health's development activities in Alexandria. He also examined the governorate's other medical institutions, including the Al-Amiriya General Hospital, Ras Al-Tin General Hospital, and Gamal Abdel Nasser Hospital.

Healthcare Policies and Reimbursement Scenarios

The regulation and reimbursement of lung cancer therapeutics in Egypt are overseen by several entities, including the Egyptian Ministry of Health and the Egyptian Drug Authority. The Egyptian healthcare system provides coverage for certain lung cancer therapeutics through the national health insurance program. The presence of the Egyptian Drug Authority will help control the country’s drug market, which, without this level of regulation has numerous problems and safety concerns — including a market infiltrated by fake drugs.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.